Inovio Pharmaceuticals (INO) Gains from Equity Investments (2010 - 2018)
Inovio Pharmaceuticals (INO) posted Gains from Equity Investments of -$228665.0 for Q3 2018, up 12.04% sequentially from -$259971.0 in Q2 2018, and up 45.98% YoY from -$156641.4 in Q3 2017.
Inovio Pharmaceuticals (INO) Gains from Equity Investments (2010 - 2018) Analysis & Trends
Inovio Pharmaceuticals has reported Gains from Equity Investments for 9 years, with the latest figure at -$228665.0 in Q3 2018.
- Quarterly Gains from Equity Investments rose 45.98% year-over-year to -$228665.0 in Q3 2018, while the trailing twelve-month figure through Jun 2019 was -$228665.0 (up 79.85% YoY) and the FY2018 annual result came in at -$360795.0, up 55.28% from the prior year.
- Gains from Equity Investments improved to -$228665.0 in Q3 2018 per INO's latest filing, from -$259971.0 in the prior quarter.
- Over five years, Gains from Equity Investments peaked at $505926.0 in Q1 2014 and troughed at -$824390.0 in Q2 2014.
- A 5-year average of -$95835.4 and a median of -$2691.0 in 2016 frame the typical range for Gains from Equity Investments.
- The sharpest annual moves came in 2016 and 2017: Gains from Equity Investments jumped 33263.41% in 2016, then sank 15630.06% in 2017.
- Over 5 years, Gains from Equity Investments stood at -$143659.0 in 2014, then soared by 302.09% to $290316.0 in 2015, then tumbled by 322.13% to -$644888.0 in 2016, then increased by 10.13% to -$579546.0 in 2017, then soared by 60.54% to -$228665.0 in 2018.
- According to Business Quant data, Gains from Equity Investments over the past three periods registered -$228665.0, -$259971.0, and $127841.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Inovio Pharmaceuticals | 96.32 Mn | 96.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -228,665.00 |
| Sep 30, 2018 | -228,665.00 |
| Jun 30, 2018 | -259,971.00 |
| Jun 30, 2018 | -259,971.00 |
| Mar 31, 2018 | 127,841.00 |
| Mar 31, 2018 | 127,841.00 |
| Dec 31, 2017 | -579,546.00 |
| Dec 31, 2017 | -579,546.00 |
| Sep 30, 2017 | -423,296.00 |
| Sep 30, 2017 | -423,296.00 |
| Jun 30, 2017 | 312,500.00 |
| Jun 30, 2017 | 312,500.00 |
| Mar 31, 2017 | -116,477.00 |
| Mar 31, 2017 | -116,477.00 |
| Dec 31, 2016 | -644,888.00 |
| Dec 31, 2016 | -644,888.00 |
| Sep 30, 2016 | -2,691.00 |
| Sep 30, 2016 | -2,691.00 |
| Jun 30, 2016 | 110,656.00 |
| Jun 30, 2016 | 110,656.00 |